Clinical Outcomes of Toric Implantable Collamer Lens implantation.
10.3341/jkos.2009.50.6.839
- Author:
Jae Moon YOON
1
;
Sang Jung MOON
;
Kyung Hun LEE
Author Information
1. Department of Ophthalmology, Sungmo Eye Hospital, Busan, Korea. sungmo@sungmo.co.kr
- Publication Type:Original Article
- Keywords:
Myopic astigmatism;
Toric ICL;
Toric Implantable Collamer Lens
- MeSH:
Astigmatism;
Eye;
Humans;
Myopia;
Postoperative Complications;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2009;50(6):839-851
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To assess the efficacy of the Toric Implantable Collamer Lens (Toric ICL) to treat moderate to high myopic astigmatism. METHODS: Toric ICL was implanted in 77 eyes of 40 patients with myopia (spherical equivalent [SE] between 3.5 and 18.5 diopters [D]) and astigmatism between 1 and 6 D. The patients were followed up for at least 3 months. Uncorrected visual acuity (UCVA), refraction, best spectacle-corrected visual acuity (BSCVA), adverse events, and postoperative complications were evaluated. RESULTS: At 3months postoperatively, the proportion of eyes with 1.0 or better UCVA (56 eyes out of 77 eyes, 72.7%) was significantly greater than the proportion of eyes with preoperative 1.0 or better BSCVA (38 eyes out of 77 eyes, 49.4%). The mean manifest refractive cylinder dropped from 2.78D (+/-1.05) at baseline to 0.35D (+/-0.34) postoperatively, an 87.4% decrease in astigmatism. Mean manifest refraction SE (MRSE) improved from -9.93D (+/-2.66) preoperatively to 0.15D (+/-0.33) postoperatively. A total of 96.1% of eyes were predicted accurately to within +/-0.75D of predicted MRSE. Mean improvement in BSCVA was 0.79lines; there were no eyes that lost two lines of BSCVA after 3 months postoperatively. CONCLUSIONS: The results support the efficacy and predictability of Toric ICL implantation to treat moderate to high myopic astigmatism.
